Optimi Health Corp. (CSE: OPTI, Nasdaq: OPTH) has announced detailed 2027 plans for two psychedelic drug candidates — a Phase 2b trial of naturally derived psilocybin OPTI-101 in major depressive disorder and a Health Canada-cleared Phase 3 trial of MDMA candidate OPTI-201 in PTSD. The Vancouver-based, commercial-stage pharmaceutical company also disclosed a shares-for-debt settlement with its Chief Executive Officer. Investors may be watching the announcements closely as the company advances multiple clinical programmes simultaneously toward potential U.S. regulatory filings.

Key Points

  • Optimi Health Corp. (CSE: OPTI, Nasdaq: OPTH, FSE: 8BN) is a Health Canada-licensed GMP manufacturer of psychedelic drug products based in Princeton, British Columbia.
  • OPTI-101 Phase 2b dosing is expected to begin Q1 2027 in 200 adults with severe MDD, with topline data anticipated in 2028; OPTI-201 Phase 3 in 100 veterans and front-line workers with PTSD is also expected to initiate in 2027.
  • The board approved settling US$240,000 in unpaid CEO compensation through a shares-for-debt issuance, subject to a definitive agreement and regulatory approval.
  • Investors should watch for Health Canada review of the amended OPTI-101 protocol and planned FDA IND filings for both programmes.

OPTI-101 Phase 2b Design Targets Severe Major Depressive Disorder

Optimi's amended OPTI-101 protocol converts the originally authorised single-arm, open-label study into a randomised, double-blind, active placebo-controlled Phase 2b trial enrolling 200 adults aged 18 to 65 with severe MDD, defined by a Montgomery-Åsberg Depression Rating Scale score of 30 or higher. The primary endpoint is change in MADRS at Week 3, assessed by independent central raters. Durability data, including response and remission rates, will be tracked through 12 months. The company states it expects to fund this trial from cash on hand, and no interim efficacy analysis is planned. The amended protocol is currently under review by Health Canada.

OPTI-201 MDMA Programme Targets Veterans and Front-Line Workers With PTSD

OPTI-201 consists of GMP MDMA capsules manufactured in Canada and already prescribed in Australia for PTSD since October 2024. Optimi is assuming sponsorship of a Health Canada-cleared Phase 3 open-label study in 100 veterans and front-line workers, including military personnel, police, paramedics, firefighters, and healthcare workers. Participants will receive two supervised dosing sessions two to three weeks apart, with the primary endpoint measuring change in Clinician-Administered PTSD Scale total severity score from baseline to Week 8. The company also plans to file a U.S. IND for OPTI-201 in 2027 to position the product as a potential option if MDMA-assisted therapy receives U.S. approval.

Board Approves Shares-for-Debt Settlement With CEO Dane Stevens

The board has approved settling US$240,000 of unpaid compensation owed to Chief Executive Officer Dane Stevens, accrued at US$120,000 per year for October 2024 to October 2026, through the issuance of 114,285 common shares at US$2.10 per share. The settlement is classified as a related-party transaction under Multilateral Instrument 61-101 because Mr. Stevens is both a director and senior officer. The board approved the transaction unanimously, with Mr. Stevens declaring his interest and abstaining from voting. Closing remains subject to execution of a definitive agreement and any required regulatory approvals. Shares issued will carry a statutory hold period of four months and one day from issuance.